JMX0286 is a potent, specific and allosteric inhibitor against SARS-CoV-2 3CLpro with IC50 of 4.8 uM in FRET based screening assays, shows strong inhibition of SARS-CoV-2 virus with EC50 of 2.25 uM in A549-hACE2 cells.

Jun9-57-3R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.05 uM.

Jun9-62-2R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.43 uM.

Jun9-88-6R is a potent, selective, covalent SARS-CoV-2 Mpro inhibitor with IC50 of 0.08 uM.

KSL-128114 (KLS 128114) is a highly potent and metabolically stable peptide inhibitor that binds to the PDZ1 domain of syntenin (KD=0.3 uM), inhibits SARS-CoV-2 infection by blocking the endosomal entry of the virus.

MAC-5576 (MAC5576) is a small molecule, covalent inhibitor of coronavirus SARS-CoV 3CLpro with IC50 of 0.5 uM, inhibits SARS-CoV-2 3CL protease with IC50 of 0.093 uM.

MAT-POS-e194df51-1 is potent, selective and noncovalent SARS-CoV-2 main protease (SARS-CoV-2 Mpro) inhibitor with IC50 of 36.8 nM, shows antiviral activity with EC50 of 64 nM in A549-ACE2-TMPRSS2 cells.

MDOLL-0229 is a selective small molecule inhibitor for SARS-CoV-2 Mac1 with IC50 of 2.1 uM, inhibits coronavirus replication.

MI-30 (SARS-CoV-2 Mpro inhibitor MI-30) is a potent, selective SARS-CoV-2 Mpro inhibitor with IC50 of 17.2 nM.

MK-7845 is a potent, reversible covalent SARS-CoV-2 3CLPro inhibitor with IC50 of 8.7 nM, inhibits wild-type SARS-CoV-2 3CLPro in SARS-CoV-2 reporter replicon assay in A549 cells with IC50 of 15 nM.

ML300 (ML 300) is a potent, selective, noncovalent inhibitor of the SARS-CoV 3CL protease (3CLpro) with IC50 of 4.11 uM, inhibits SARS-CoV-2 3CLpro with IC50 of 4.99 uM.

Molnupiravir N-1 is an impurity chemical of Molnupiravir (EIDD-2801, MK4482), which is anti-SARS-CoV-2 for treatment of COVID-19.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 8.5 nM.

MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 33 nM, completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 uM and A549 cells at 0.16-0.31 uM.

MU-UNMC-1 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 0.67 uM in human bronchial epithelial cells.

MU-UNMC-2 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 1.72 uM in human bronchial epithelial cells.

NACE2i is a cell permeable, specific and selective peptide inhibitor of nuclear ACE2, inhibits binding between IMP1α and ACE2 and SARS-CoV-2 viral replication. NACE2i specifically targets nuclear ACE2 and not other nuclear proteins targeted by the importin pathway. NACE2i has no impact on ACE2 enzymatic activity. NACE2i prevents inflammation and macrophage infiltration, and increases NK cell infiltration in bronchioles. NACE2i treatment increases the levels of the active histone mark, H3K27ac, restores host translation in infected hamster bronchiolar cells, and leads to an enrichment in methylated ACE2 in hamster bronchioles and lung macrophages. NACE2i has a dual mode of action: suppressing the lethal inflammation in severe COVID-19 and inhibiting viral replication by restoring host translation of anti-viral cytokines.

NBCoV1 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=17 nM, SARS-CoV-2 IC50=51 nM, MERS-CoV IC50=75 nM, cell-based single-cycle assays).

NBCoV2 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=13.8 nM, SARS-CoV-2 IC50=22.8 nM, MERS-CoV IC50=77 nM, cell-based single-cycle assays). NBCoV2 also has potent antiviral activity against all mutant pseudoviruses carrying single-, double-, or triple-mutations featured in the B.1.1.7 UK, B.1.351 RSA, and B.1.617.2 Delta variants (IC50=30-80 nM). NBCoV2 completely preventing the induction of any virus-induced CPE (IC100=1.25 uM, SARS-CoV-2 (US_WA-1/2020)). NBCoV2 bind to the S2 subdomain of the SARS-CoV-2 trimer, thus, inhibits the fusion of CoVs with the cell membran, and is specific for the SARS-CoV-2 S protein.

NSC 621601 (Compound Q34) is a potent, specific inhibitor of SARS-CoV-2 cellular entry with IC50 of 15 uM.

Olgotrelvir (STI-1558) is a next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, Olgotrelvir is the prodrug of AC1115.

P2119 (P-2119) is an anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor.